Business
Neurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-Person and Virtual Annual Meeting
SAN DIEGO, March 24, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, March 24, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders program and telemedicine research at the American Academy of Neurology (AAN) Annual Meeting being held in person April 2–7, 2022 in Seattle and virtually April 24–26.\n\n \n \n \n \n \n \n\n \nNeurocrine Biosciences will present new findings from a literature review and gap analysis on telemedicine research in serious mental illness and movement disorders. The analysis found that a meaningful evidence gap exists regarding the impact of telemedicine on key outcomes for individuals living with serious mental illness and movement disorders, revealing the need for further research into the benefits and limitations of telemedicine. The company will also present encore data from observational, clinical survey and real-world studies across neurological treatments INGREZZA® (valbenazine) capsules and ONGENTYS® (opicapone) capsules and patient populations.\n\"The new telemedicine findings we'll be presenting at AAN provide insight into the clinical implications of telemedicine in serious mental illness and movement disorders, which may help to inform how healthcare professionals approach treatment,\" said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. \"Additionally, the INGREZZA data presentations continue to demonstrate our commitment to deepening our understanding of treatment outcomes in patient populations we serve.\"\nPresentations include:\nINGREZZA – Tardive Dyskinesia \nTeleSCOPE: A Real-World Study of Telehealth for the Detection and Treatment of Drug-Induced Movement Disorders (Poster #002 in Neighborhood 11 during Session P1 – Movement Disorders: COVID, Telemedicine and Community)Once-Daily Valbenazine is Effective for Tardive Dyskinesia in Elderly Patients (≥65 years) (Poster #004 in Neighborhood 11 during Session P6 – Movement Disorders: Tardive Dyskinesia and PD Imaging)ONGENTYS – Parkinson's Disease (in collaboration with BIAL)\nPatients' Preferences for Adjunctive Parkinson's Disease Treatments: A Discrete-Choice Experiment (Poster #007 in Neighborhood 11 during Session P11 – Movement Disorders: PD Therapeutics)Telemedicine\nThe Impact of Telemedicine on Serious Mental Illness and Movement Disorders: A Literature Review and Gap Analysis (Poste...